{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:18:48Z","timestamp":1787026728682,"version":"build-2736575974"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The past decade has seen the development of immunotherapy for the treatment of multiple myeloma (MM), beginning with monoclonal antibodies (mAbs) in the relapsed and refractory setting and culminating in the market approval of chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (BsAbs). The medical community is evaluating the efficacy and safety of these targeted immunotherapies, most of which currently target B-cell maturation antigen (BCMA) on the surface of plasma cells. Two anti-BCMA CAR-T products are available for treating relapsed or refractory MM: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). Ide-cel and cilta-cel demonstrate the ability to induce deep responses in heavily pretreated diseases, including patients with triple-class-refractory and penta-refractory diseases. However, there are key similarities and differences regarding these agents, unknowns regarding their comparative efficacy and toxicity, and mechanisms underlying resistance to these new immunotherapies. This review discusses CAR-T cell therapy in relapsed refractory MM, with a focus on efficacy, toxicities, and the evolving trajectories of these therapies in the USA, as well as access in Turkey.<\/jats:p>","DOI":"10.3389\/fmed.2024.1413825","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T03:48:18Z","timestamp":1724903298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey"],"prefix":"10.3389","volume":"11","author":[{"given":"Goker","family":"Hakan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelkitli","family":"Engin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karakulak Aladag","family":"Elifcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demiroglu","family":"Haluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turgut","family":"Mehmet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambhampati","family":"Suman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krem","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","article-title":"Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy","volume":"92","author":"Dingli","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.transci.2016.01.011","article-title":"Chimeric antigen receptor T cell treatment in hematologic malignancies","volume":"54","author":"Goker","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3390\/biom10101387","article-title":"Anti-BCMA immunotoxins: design, production, and preclinical evaluation","volume":"10","author":"Bera","year":"2020","journal-title":"Biomol Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3390\/vaccines11111721","article-title":"CAR-T-cell therapy in multiple myeloma: B-cell maturation antigen (BCMA) and beyond","volume":"11","author":"Mishra","year":"2023","journal-title":"Vaccines"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA approval summary: Idecabtagene Vicleucel for relapsed or refractory multiple myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/bjh.19302","article-title":"Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: a real-world multicentre study","volume":"204","author":"Dima","year":"2024","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3324\/haematol.2023.283888","article-title":"Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/refractory multiple myeloma: U.S. myeloma immunotherapy consortium real world experience","volume":"109","author":"Hashmi","year":"2023","journal-title":"Haematologica"},{"key":"ref12","volume-title":"FDA approves ide-Cel in previously treated multiple myeloma","author":"Pelosci","year":"2024"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"ref20","volume-title":"FDA approves Cilta-Cel for relapsed\/refractory myeloma after 1 therapy","author":"Mauro","year":"2024"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jtct.2023.10.022","article-title":"Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Anderson","year":"2024","journal-title":"Transplant Cell Ther."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","article-title":"Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"37","author":"Martin","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.06.012","article-title":"Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma","author":"Wesson","year":"2024","journal-title":"Transplant Cell Ther."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood.2022017414","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1182\/bloodadvances.2023010653","article-title":"A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma","volume":"7","author":"Strati","year":"2023","journal-title":"Blood Adv"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","article-title":"Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy","volume":"29","author":"Davis","year":"2023","journal-title":"Transplant Cell Ther."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.46989\/001c.115932","article-title":"Managing infection complications in the setting of chimeric antigen receptor T cell (CAR-T) therapy","volume":"6","author":"Ahmed","year":"2024","journal-title":"Clin Hematol Int"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated Hemophagocytic Lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1182\/blood.2024024446","article-title":"Data mining for second malignancies after CAR-T","volume":"143","author":"Heslop","year":"2024","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"ref37","article-title":"P-BCMA-ALLO1 allogeneic CAR-T cells in the treatment of subjects with Multiple Myeloma (MM)","author":"Schinkel","year":"2024"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T therapy technologies: has the promise been met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"S2666","DOI":"10.1016\/j.jtct.2024.05.011","article-title":"TACTUM: Trends in access to cellular therapies in multiple myeloma, Perspectives of Treating Versus Referring Physicians","volume":"18","author":"Atallah","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"s373","DOI":"10.1016\/j.jtct.2023.12.523","article-title":"The GLAMM1 study - global access to myeloma medications: potential barriers to chimeric antigen receptors (CART) and T-cell-engaging bispecific antibodies (TCE) globally","volume":"30","author":"Rawan Atallah","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1413825\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T03:48:22Z","timestamp":1724903302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1413825\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":40,"alternative-id":["10.3389\/fmed.2024.1413825"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1413825","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"article-number":"1413825"}}